Cipla Limited announced that the United States Food and Drug Administration (USFDA) has classified its inspection of the InvaGen manufacturing facility as Voluntary Action Indicated (VAI). This classification pertains to the inspection conducted at the company’s wholly-owned subsidiary’s facility in Central Islip, New York, USA, between July 13th and July 17th, 2026. The communication regarding this classification was received on August 28th, 2026.
USFDA Inspection Outcome for InvaGen Facility
Cipla Limited has received communication from the United States Food and Drug Administration (USFDA) regarding the inspection of its subsidiary, InvaGen Pharmaceuticals Inc. The inspection took place at the manufacturing facility located in Central Islip, Long Island, New York, USA, from July 13th, 2026, to July 17th, 2026. The USFDA has officially classified this inspection as Voluntary Action Indicated (VAI).
Positive Classification Announced
This classification, received via communication dated August 28th, 2026, indicates that the USFDA has noted certain observations during the inspection, but these are not considered to be of a significant or critical nature that would warrant further regulatory action beyond what is voluntarily undertaken by the company. The VAI classification is generally viewed as a favorable outcome for manufacturing facilities undergoing regulatory scrutiny.
This update follows Cipla’s previous intimation on July 18th, 2026, regarding the commencement of the USFDA inspection at the InvaGen facility.
Source: BSE
